Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based drugs to address various unmet medical needs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin- antagonist that is in Phase II b clinical trial for the treatment of ulcerative colitis, as well as for treating chronic pouchitis, a gastrointestinal (GI) condition that occurs in post-surgical inflammatory bowel disease (IBD) patients; PTG-200, an oral interleukin-23 receptor antagonist, which is in Phase I clinical trial for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic, which has completed Phase I study for use in the treatment of beta-thalassemia, as well as for treating other diseases, such as hereditary hemochromatosis, polycythemia vera, siderophilic infections, and liver fibrosis. It is also developing an oral peptide targeting a GI condition other than IBD. The company was founded in 2006 and is headquartered in Newark, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-474-0170
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.92 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions
What is Protagonist Therapeutics' stock symbol?
Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."
How were Protagonist Therapeutics' earnings last quarter?
Protagonist Therapeutics Inc (NASDAQ:PTGX) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.15. The business had revenue of $2.35 million for the quarter, compared to analyst estimates of $5.45 million. Protagonist Therapeutics had a negative net margin of 125.87% and a negative return on equity of 33.94%. View Protagonist Therapeutics' Earnings History.
When is Protagonist Therapeutics' next earnings date?
What price target have analysts set for PTGX?
5 equities research analysts have issued 12 month price targets for Protagonist Therapeutics' shares. Their predictions range from $13.00 to $21.00. On average, they anticipate Protagonist Therapeutics' share price to reach $17.25 in the next year. This suggests a possible upside of 40.2% from the stock's current price. View Analyst Price Targets for Protagonist Therapeutics.
What is the consensus analysts' recommendation for Protagonist Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protagonist Therapeutics.
Has Protagonist Therapeutics been receiving favorable news coverage?
News stories about PTGX stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Protagonist Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Protagonist Therapeutics' key competitors?
Some companies that are related to Protagonist Therapeutics include Homology Medicines (FIXX), Rhythm Pharmaceuticals (RYTM), CannTrust (CNTTF), Retrophin (RTRX), Clementia Pharmaceuticals (CMTA), Kiniksa Pharmaceuticals (KNSA), Deciphera Pharmaceuticals (DCPH), Vanda Pharmaceuticals (VNDA), Amphastar Pharmaceuticals (AMPH), MacroGenics (MGNX), Alder Biopharmaceuticals (ALDR), Dicerna Pharmaceuticals (DRNA), Principia Biopharma (PRNB), Radius Health (RDUS) and Advanz Pharma (CXRXF).
What other stocks do shareholders of Protagonist Therapeutics own?
Who are Protagonist Therapeutics' key executives?
Protagonist Therapeutics' management team includes the folowing people:
- Dr. Dinesh V. Patel, CEO, Pres, Interim Principal Financial Officer, Sec. & Director (Age 62)
- Dr. Richard S. Shames, Chief Medical Officer (Age 59)
- Dr. David Y. Liu, Chief Scientific Officer and Head of R&D (Age 69)
- Mr. Niall Murphy, Interim Principal Accounting Officer (Age 45)
- Dr. Mark Smythe, VP of Technology (Age 54)
When did Protagonist Therapeutics IPO?
(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at a price of $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.
Who are Protagonist Therapeutics' major shareholders?
Protagonist Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Perceptive Advisors LLC (5.65%), Great Point Partners LLC (3.95%), Millennium Management LLC (2.85%), Dimensional Fund Advisors LP (2.03%) and Dimensional Fund Advisors LP (2.03%). Company insiders that own Protagonist Therapeutics stock include Bryan Giraudo, David Y Liu, Dinesh V Ph D Patel, Richard S Shames, Thomas P O'neil and X LP Canaan. View Institutional Ownership Trends for Protagonist Therapeutics.
Which institutional investors are selling Protagonist Therapeutics stock?
PTGX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, Alambic Investment Management L.P., Two Sigma Advisers LP, American Century Companies Inc., Algert Global LLC, Great Point Partners LLC and Tekla Capital Management LLC. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, Dinesh V Ph D Patel, Richard S Shames and X LP Canaan. View Insider Buying and Selling for Protagonist Therapeutics.
Which institutional investors are buying Protagonist Therapeutics stock?
PTGX stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Fosun International Ltd, Barclays PLC, BlackRock Inc. and Bank of America Corp DE. View Insider Buying and Selling for Protagonist Therapeutics.
How do I buy shares of Protagonist Therapeutics?
Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Protagonist Therapeutics' stock price today?
One share of PTGX stock can currently be purchased for approximately $12.30.
How big of a company is Protagonist Therapeutics?
Protagonist Therapeutics has a market capitalization of $287.21 million and generates $30.92 million in revenue each year. The company earns $-38,920,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis.
What is Protagonist Therapeutics' official website?
How can I contact Protagonist Therapeutics?
Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at 510-474-0170 or via email at [email protected]
MarketBeat Community Rating for Protagonist Therapeutics (NASDAQ PTGX)
MarketBeat's community ratings are surveys of what our community members think about Protagonist Therapeutics and other stocks. Vote "Outperform" if you believe PTGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
